Regulation of the growth hormone/insulin-like growth factor-I axis in HIV disease

Endocrinologist

Volumn 11, Issue 3, 2001, Pages 188-195

  Meininger, Gary ^a,b   Grinspoon, Steven ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOSYNTHESIS; BODY COMPOSITION; BODY MASS; BODY WEIGHT; DISEASE ASSOCIATION; EDEMA; GENE CONTROL; GROWTH HORMONE RELEASE; HORMONE ACTION; HORMONE RELEASE; HORMONE RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIPOLYSIS; MUSCLE ATROPHY; MUSCLE MASS; MYALGIA; NUTRITIONAL STATUS; OBESITY; REVIEW; WASTING SYNDROME;

EID: 0034968717     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200105000-00005     Document Type: Review

References (51)

1. Growth hormone therapy for protein catabolism
2. Effects of rhIGF-I administration on bone turnover during short-term fasting
3. Reduction of plasma immunoreactive somatomedin C during fasting in humans
4. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults
5. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins
6. The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa
7. Determinants of circulating insulin-like growth factor-I
8. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay
9. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man
10. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity
11. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion
12. Arginine potentiates the GHRH-but not the pyridostigmine-induced GH secretion in normal short children: Further evidence for a somatostatin suppressing effect of arginine
13. Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: Effects of gender
14. The relationship between growth hormone kinetics and sarcopenia in postmenopausal women: The role of fat mass and leptin
15. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects
16. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome
17. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting
18. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system
19. Assessment of growth hormone dynamics in the HIV lipodystrophy syndrome
20. HIV wasting syndrome: Treatment update
21. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome
22. Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting
23. Human immunodeficiency virus-associated wasting and mechanisms of cachexia associated with inflammation
24. Endocrine disorders in men infected with human immunodeficiency virus
25. Changes in the hypothalamic-pituitary-gonadal axis in human immunodeficiency virus-infected homosexual men
26. Transient exposure of human myoblasts to tumor necrosis factor-alpha inhibits serum and insulin-like growth factor-I stimulated protein synthesis
27. Treatments for wasting in patients with the acquired immunodeficiency syndrome
28. Proteolysis of insulin-like growth factor-binding protein-3 in human immunodeficiency virus-positive children who fail to thrive
29. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors
30. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
31. Visceral abdominal-fat accumulation associated with use of indinavir
32. Serum markers of metabolic dysregulation in HIV disease
33. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
34. Treatment with prolease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
35. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS)
36. Biosynthetic human growth hormone preserves both muscle protein synthesis and the decrease in muscle-free glutamine, and improves whole-body nitrogen economy after operation
37. Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients
38. Failure of anabolism in malnourished cancer patients receiving growth hormone: A clinical research center study
39. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection
40. Recombinant human growth hormone in patients with HIV-associated wasting: A randomized, placebo-controlled trial
41. Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease
42. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients
43. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting: A randomized, double-blind, placebo-controlled trial
44. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection
45. Treatment of dorsocervical fat pads (buffalo hump) and truncal adiposity with serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART
46. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV
47. The effects of recombinant human growth hormone on glucose metabolism and body composition in HIV-positive subjects with fat accumulation syndromes
48. Effect of recombinant human growth hormone on acute and chronic human immunodeficiency virus infection in vitro
49. Recombinant mammalian cell-derived somatropin: A review of its pharmacological properties and therapeutic potential in the management of wasting associated with HIV infection